D. E. Shaw & Co., Inc. Keros Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 18,874 shares of KROS stock, worth $862,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,874Holding current value
$862,541% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding KROS
# of Institutions
153Shares Held
26.7MCall Options Held
47.6KPut Options Held
34.5K-
Black Rock Inc. New York, NY2.17MShares$99 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$73.1 Million0.18% of portfolio
-
State Street Corp Boston, MA1.56MShares$71.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.55MShares$70.6 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.44MShares$65.6 Million16.21% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.18B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...